<DOC>
	<DOCNO>NCT01567085</DOCNO>
	<brief_summary>Primary Objective : To evaluate safety potential efficacy eculizumab prevent Antibody Mediated Rejection ( AMR ) sensitize recipient decease donor kidney transplant .</brief_summary>
	<brief_title>Safety &amp; Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Male female patient â‰¥ 18 year old 2 . Patients Stage V chronic kidney disease receive kidney transplant decease donor sensitized 3 . History prior exposure HLA ( Human Leukocyte Antigen ) : Prior solid organ tissue allograft Pregnancy Blood transfusion Prior exposure specific donor 's HLA 1 . Has receive treatment eculizumab time prior enrol study 2 . ABO ( A , B O Blood GlycoproteinsBlood Type ) incompatible decease donor 3 . History severe cardiac disease 4 . Prior splenectomy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>